HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) has risen by more than 5% as two of its drugs have been approved by the National Medical Products Administration for clinical trials.

Jiangsu Hengrui Pharmaceuticals (01276) rose more than 5%, as of press time, up 5.61% to 74.3 Hong Kong dollars, with a turnover of 126 million Hong Kong dollars. On the news front, on the evening of November 25, Jiangsu Hengrui Pharmaceuticals announced that it had received approval from the National Medical Products Administration for two drug clinical trial approval notices. The announcement stated that HRS-8364 tablets will soon conduct clinical trials in advanced solid tumors. Currently, there are no similar drugs approved for market at home and abroad. As of now, the total research and development investment in the HRS-8364 tablet project is approximately 21.65 million yuan. In addition, the injection of rituximab single anti-cancer drug will soon conduct clinical trials in patients with HER2-amplified solid tumors. As of now, the total research and development investment in the injection of rituximab single anti-cancer drug project is approximately 1.41 billion yuan.